Literature DB >> 23053135

Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion.

Kevin F Bieniek1, Melissa E Murray, Nicola J Rutherford, Monica Castanedes-Casey, Mariely DeJesus-Hernandez, Amanda M Liesinger, Matthew C Baker, Kevin B Boylan, Rosa Rademakers, Dennis W Dickson.   

Abstract

An expanded GGGGCC hexanucleotide repeat in C9ORF72 is the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal lobar degeneration associated with TDP-43 pathology (FTLD-TDP). In addition to TDP-43-positive neuronal and glial inclusions, C9ORF72-linked FTLD-TDP has characteristic TDP-43-negative neuronal cytoplasmic and intranuclear inclusions as well as dystrophic neurites in the hippocampus and cerebellum. These lesions are immunopositive for ubiquitin and ubiquitin-binding proteins, such as sequestosome-1/p62 and ubiquilin-2. Studies examining the frequency of the C9ORF72 mutation in clinically probable Alzheimer's disease (AD) have found a small proportion of AD cases with the mutation. This prompted us to systematically explore the frequency of Alzheimer-type pathology in a series of 17 FTLD-TDP cases with mutations in C9ORF72 (FTLD-C9ORF72). We identified four cases with sufficient Alzheimer-type pathology to meet criteria for intermediate-to-high-likelihood AD. We compared AD pathology in the 17 FTLD-C9ORF72 to 13 cases of FTLD-TDP linked to mutations in the gene for progranulin (FTLD-GRN) and 36 cases of sporadic FTLD (sFTLD). FTLD-C9ORF72 cases had higher Braak neurofibrillary tangle stage than FTLD-GRN. Increased tau pathology in FTLD-C9ORF72 was assessed with thioflavin-S fluorescent microscopy-based neurofibrillary tangle counts and with image analysis of tau burden in temporal cortex and hippocampus. FTLD-C9ORF72 had significantly more neurofibrillary tangles and higher tau burden compared with FTLD-GRN. The differences were most marked in limbic regions. On the other hand, sFTLD and FTLD-C9ORF72 had a similar burden of tau pathology. These results suggest FTLD-C9ORF72 has increased propensity for tau pathology compared to FTLD-GRN, but not sFTLD. The accumulation of tau as well as lesions immunoreactive for ubiquitin and ubiquitin-binding proteins (p62 and ubiquilin-2) suggests that mutations in C9ORF72 may involve disrupted protein degradation that favors accumulation of multiple different proteins.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053135      PMCID: PMC3551994          DOI: 10.1007/s00401-012-1048-7

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  53 in total

1.  Are amyotrophic lateral sclerosis patients cognitively normal?

Authors:  C Lomen-Hoerth; J Murphy; S Langmore; J H Kramer; R K Olney; B Miller
Journal:  Neurology       Date:  2003-04-08       Impact factor: 9.910

2.  Diagnosis of Alzheimer's disease.

Authors:  Z S Khachaturian
Journal:  Arch Neurol       Date:  1985-11

3.  The overlap of amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  Catherine Lomen-Hoerth; Thomas Anderson; Bruce Miller
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

4.  Ubiquitin immunoreactive structures in normal human brains. Distribution and developmental aspects.

Authors:  D W Dickson; A Wertkin; Y Kress; H Ksiezak-Reding; S H Yen
Journal:  Lab Invest       Date:  1990-07       Impact factor: 5.662

5.  Argyrophilic grain disease: neuropathology, frequency in a dementia brain bank and lack of relationship with apolipoprotein E.

Authors:  Takashi Togo; Natalie Cookson; Dennis W Dickson
Journal:  Brain Pathol       Date:  2002-01       Impact factor: 6.508

6.  Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration.

Authors:  Keith A Josephs; Yoshio Tsuboi; Natalie Cookson; Hilary Watt; Dennis W Dickson
Journal:  Arch Neurol       Date:  2004-10

7.  Phases of A beta-deposition in the human brain and its relevance for the development of AD.

Authors:  Dietmar R Thal; Udo Rüb; Mario Orantes; Heiko Braak
Journal:  Neurology       Date:  2002-06-25       Impact factor: 9.910

8.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein.

Authors:  Giles D J Watts; Jill Wymer; Margaret J Kovach; Sarju G Mehta; Steven Mumm; Daniel Darvish; Alan Pestronk; Michael P Whyte; Virginia E Kimonis
Journal:  Nat Genet       Date:  2004-03-21       Impact factor: 38.330

9.  An MND/ALS phenotype associated with C9orf72 repeat expansion: abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline.

Authors:  Claire Troakes; Satomi Maekawa; Lokesh Wijesekera; Boris Rogelj; László Siklós; Christopher Bell; Bradley Smith; Stephen Newhouse; Caroline Vance; Lauren Johnson; Tibor Hortobágyi; Aleksey Shatunov; Ammar Al-Chalabi; Nigel Leigh; Christopher E Shaw; Andrew King; Safa Al-Sarraj
Journal:  Neuropathology       Date:  2011-12-19       Impact factor: 1.906

10.  Identification of ubiquilin, a novel presenilin interactor that increases presenilin protein accumulation.

Authors:  A L Mah; G Perry; M A Smith; M J Monteiro
Journal:  J Cell Biol       Date:  2000-11-13       Impact factor: 10.539

View more
  45 in total

1.  C9ORF72 repeat expansions in cases with previously identified pathogenic mutations.

Authors:  Marka van Blitterswijk; Matthew C Baker; Mariely DeJesus-Hernandez; Roberta Ghidoni; Luisa Benussi; Elizabeth Finger; Ging-Yuek R Hsiung; Brendan J Kelley; Melissa E Murray; Nicola J Rutherford; Patricia E Brown; Thomas Ravenscroft; Bianca Mullen; Peter E A Ash; Kevin F Bieniek; Kimmo J Hatanpaa; Anna Karydas; Elisabeth McCarty Wood; Giovanni Coppola; Eileen H Bigio; Carol Lippa; Michael J Strong; Thomas G Beach; David S Knopman; Edward D Huey; Marsel Mesulam; Thomas Bird; Charles L White; Andrew Kertesz; Dan H Geschwind; Vivianna M Van Deerlin; Ronald C Petersen; Giuliano Binetti; Bruce L Miller; Leonard Petrucelli; Zbigniew K Wszolek; Kevin B Boylan; Neill R Graff-Radford; Ian R Mackenzie; Bradley F Boeve; Dennis W Dickson; Rosa Rademakers
Journal:  Neurology       Date:  2013-09-11       Impact factor: 9.910

Review 2.  Mechanisms of toxicity in C9FTLD/ALS.

Authors:  Tania F Gendron; Veronique V Belzil; Yong-Jie Zhang; Leonard Petrucelli
Journal:  Acta Neuropathol       Date:  2014-01-07       Impact factor: 17.088

3.  Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS.

Authors:  Peter E A Ash; Kevin F Bieniek; Tania F Gendron; Thomas Caulfield; Wen-Lang Lin; Mariely Dejesus-Hernandez; Marka M van Blitterswijk; Karen Jansen-West; Joseph W Paul; Rosa Rademakers; Kevin B Boylan; Dennis W Dickson; Leonard Petrucelli
Journal:  Neuron       Date:  2013-02-12       Impact factor: 17.173

4.  Expanded C9ORF72 hexanucleotide repeat in depressive pseudodementia.

Authors:  Kevin F Bieniek; Marka van Blitterswijk; Matthew C Baker; Leonard Petrucelli; Rosa Rademakers; Dennis W Dickson
Journal:  JAMA Neurol       Date:  2014-06       Impact factor: 18.302

5.  Tau Accumulation via Reduced Autophagy Mediates GGGGCC Repeat Expansion-Induced Neurodegeneration in Drosophila Model of ALS.

Authors:  Xue Wen; Ping An; Hexuan Li; Zijian Zhou; Yimin Sun; Jian Wang; Lixiang Ma; Boxun Lu
Journal:  Neurosci Bull       Date:  2020-06-04       Impact factor: 5.203

6.  TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia.

Authors:  Alexandra M Nicholson; Nicole A Finch; Aleksandra Wojtas; Matt C Baker; Ralph B Perkerson; Monica Castanedes-Casey; Linda Rousseau; Luisa Benussi; Giuliano Binetti; Roberta Ghidoni; Ging-Yuek R Hsiung; Ian R Mackenzie; Elizabeth Finger; Bradley F Boeve; Nilüfer Ertekin-Taner; Neill R Graff-Radford; Dennis W Dickson; Rosa Rademakers
Journal:  J Neurochem       Date:  2013-07-01       Impact factor: 5.372

7.  Mixed TDP-43 proteinopathy and tauopathy in frontotemporal lobar degeneration: nine case series.

Authors:  Eun-Joo Kim; Jesse A Brown; Jersey Deng; Ji-Hye L Hwang; Salvatore Spina; Zachary A Miller; Mary G DeMay; Victor Valcour; Anna Karydas; Eliana Marisa Ramos; Giovanni Coppola; Bruce L Miller; Howard J Rosen; William W Seeley; Lea T Grinberg
Journal:  J Neurol       Date:  2018-10-15       Impact factor: 4.849

8.  Tau positron emission tomography imaging in C9orf72 repeat expansion carriers.

Authors:  C V Ly; L Koenig; J Christensen; B Gordon; H Beaumont; S Dahiya; J Chen; Y Su; B Nelson; J Jockel-Balsarotti; C Drain; G Jerome; J C Morris; A M Fagan; M B Harms; T L S Benzinger; T M Miller; B M Ances
Journal:  Eur J Neurol       Date:  2019-03-25       Impact factor: 6.089

9.  Progressive amnestic dementia, hippocampal sclerosis, and mutation in C9ORF72.

Authors:  Melissa E Murray; Kevin F Bieniek; M Banks Greenberg; Mariely DeJesus-Hernandez; Nicola J Rutherford; Marka van Blitterswijk; Ellis Niemantsverdriet; Peter E Ash; Tania F Gendron; Naomi Kouri; Matt Baker; Ira J Goodman; Leonard Petrucelli; Rosa Rademakers; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2013-08-07       Impact factor: 17.088

Review 10.  C9ORF72 mutations in neurodegenerative diseases.

Authors:  Ying Liu; Jin-Tai Yu; Yu Zong; Jing Zhou; Lan Tan
Journal:  Mol Neurobiol       Date:  2013-08-10       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.